Skip to content
HowShorted

BioXcel Therapeutics, Inc. short interest in 2023

In 2023, BioXcel Therapeutics, Inc.'s disclosed short interest ran from 8.28% of shares outstanding on 13 Jan 2023 to 10.13% on 29 Dec 2023, a change of +1.85 percentage points. The year's high was 29.90% on 14 Jul 2023 and its low 8.28% on 13 Jan 2023, averaging 14.51% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.60 days on 28 Apr 2023. Full history: BioXcel Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for BioXcel Therapeutics, Inc. in 2023

2023 in figures

Start of year
8.28% (13 Jan 2023)
End of year
10.13% (29 Dec 2023)
Change
+1.85 pp
High
29.90% (14 Jul 2023)
Low
8.28% (13 Jan 2023)
Average
14.51%
Highest days to cover
9.60 (28 Apr 2023)

Every report in 2023

BioXcel Therapeutics, Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20238.28%6.08
31 Jan 20238.76%7.07
15 Feb 20239.19%5.80
28 Feb 202310.03%7.61
15 Mar 202310.25%5.23
31 Mar 202312.40%4.62
14 Apr 202312.87%9.18
28 Apr 202312.19%9.60
15 May 202311.53%6.58
31 May 202312.84%5.12
15 Jun 202315.75%8.89
30 Jun 202317.68%1.24
14 Jul 202329.90%1.00
31 Jul 202324.27%5.96
15 Aug 202323.06%2.99
31 Aug 202315.02%4.76
15 Sep 202316.22%3.87
29 Sep 202312.22%5.69
13 Oct 202317.00%1.99
31 Oct 202319.85%1.00
15 Nov 202317.34%1.23
30 Nov 202311.75%3.28
15 Dec 20239.81%4.28
29 Dec 202310.13%4.57

See also: BioXcel Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.